

CANCER TREATMENT

Glenmark starts studies on new drug

NEW DELHI: Glenmark Pharmaceuticals on Friday announced discovery and initiation of enabling studies of an investigational new drug (IND) molecule targeted at cancer treatment. The novel clinical development candidate, GBRI342 is an antibody based on the company's proprietary BEAT platform, Glenmark Pharmaceuticals said in a regulatory filing. BEAT is Glenmark's technology for production of bi-specific antibodies. GBRI342 is the second clinical development candidate following GBRI302 based on the BEAT technology. It is also Glenmark's second clinical candidate targeting oncology indications, it added. — PTI

RSD